View Item 

Show simple item record

Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial
dc.contributor.authorHaddad, Robert
dc.contributor.authorConcha‐benavente, Fernando
dc.contributor.authorBlumenschein, George
dc.contributor.authorFayette, Jerome
dc.contributor.authorGuigay, Joel
dc.contributor.authorColevas, A. Dimitrios
dc.contributor.authorLicitra, Lisa
dc.contributor.authorKasper, Stefan
dc.contributor.authorVokes, Everett E.
dc.contributor.authorWorden, Francis
dc.contributor.authorSaba, Nabil F.
dc.contributor.authorTahara, Makoto
dc.contributor.authorJayaprakash, Vijayvel
dc.contributor.authorLynch, Mark
dc.contributor.authorLi, Li
dc.contributor.authorGillison, Maura L.
dc.contributor.authorHarrington, Kevin J.
dc.contributor.authorFerris, Robert L.
dc.date.accessioned2019-09-30T15:31:27Z
dc.date.availableWITHHELD_13_MONTHS
dc.date.available2019-09-30T15:31:27Z
dc.date.issued2019-09-15
dc.identifier.citationHaddad, Robert; Concha‐benavente, Fernando ; Blumenschein, George; Fayette, Jerome; Guigay, Joel; Colevas, A. Dimitrios; Licitra, Lisa; Kasper, Stefan; Vokes, Everett E.; Worden, Francis; Saba, Nabil F.; Tahara, Makoto; Jayaprakash, Vijayvel; Lynch, Mark; Li, Li; Gillison, Maura L.; Harrington, Kevin J.; Ferris, Robert L. (2019). "Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial." Cancer (18): 3208-3218.
dc.identifier.issn0008-543X
dc.identifier.issn1097-0142
dc.identifier.urihttps://hdl.handle.net/2027.42/151309
dc.publisherSage
dc.publisherWiley Periodicals, Inc.
dc.subject.otherphase 3 clinical trials
dc.subject.otherimmunotherapy
dc.subject.othernivolumab
dc.subject.othersquamous cell carcinoma of the head and neck
dc.titleNivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelPublic Health
dc.subject.hlbsecondlevelOncology and Hematology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/151309/1/cncr32190_am.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/151309/2/cncr32190.pdf
dc.identifier.doi10.1002/cncr.32190
dc.identifier.sourceCancer
dc.identifier.citedreferenceGillison ML, Blumenschein G Jr, Fayette J, et al. CheckMate 141: 1-year update and subgroup analysis of nivolumab as first-line therapy in patients with recurrent/metastatic head and neck cancer. Oncologist. 2018; 23: 1079 - 1082.
dc.identifier.citedreferenceEisenhauer EA, Therasse P, Bogaerts J, et al. New Response Evaluation Criteria in Solid Tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009; 45: 228 - 247.
dc.identifier.citedreferenceFerris RL, Blumenschein G Jr, Fayette J, et al. Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. Oral Oncol. 2018; 81: 45 - 51.
dc.identifier.citedreferenceFerris RL, Blumenschein G Jr, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016; 375: 1856 - 1867.
dc.identifier.citedreferenceSeymour L, Bogaerts J, Perrone A, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017; 18: e143 - e152.
dc.identifier.citedreferenceHodi FS, Ballinger M, Lyons B, et al. Immune-modified response evaluation criteria in solid tumors (imRECIST): refining guidelines to assess the clinical benefit of cancer immunotherapy. J Clin Oncol. 2018; 36: 850 - 858.
dc.identifier.citedreferenceHodi FS, Hwu WJ, Kefford R, et al. Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab. J Clin Oncol. 2016; 34: 1510 - 1517.
dc.identifier.citedreferenceBohnsack O, Ludajic K, Hoos A. Adaptation of the immune-related response criteria: irRECIST [abstract 1070P]. Ann Oncol. 2014; 25 ( suppl 4 ): iv361 - iv372.
dc.identifier.citedreferenceNishino M, Giobbie-Hurder A, Gargano M, Suda M, Ramaiya NH, Hodi FS. Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements. Clin Cancer Res. 2013; 19: 3936 - 3943.
dc.identifier.citedreferenceGeorge S, Motzer RJ, Hammers HJ, et al. Safety and efficacy of nivolumab in patients with metastatic renal cell carcinoma treated beyond progression: a subgroup analysis of a randomized clinical trial. JAMA Oncol. 2016; 2: 1179 - 1186.
dc.identifier.citedreferenceEscudier B, Motzer RJ, Sharma P, et al. Treatment beyond progression in patients with advanced renal cell carcinoma treated with nivolumab in CheckMate 025. Eur Urol. 2017; 72: 368 - 376.
dc.identifier.citedreferenceKazandjian D, Keegan P, Suzman DL, Pazdur R, Blumenthal GM. Characterization of outcomes in patients with metastatic non-small cell lung cancer treated with programmed cell death protein 1 inhibitors past RECIST version 1.1-defined disease progression in clinical trials. Semin Oncol. 2017; 44: 3 - 7.
dc.identifier.citedreferenceBeaver JA, Hazarika M, Mulkey F, et al. Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis. Lancet Oncol. 2018; 19: 229 - 239.
dc.identifier.citedreferenceLong GV, Weber JS, Larkin J, et al. Nivolumab for patients with advanced melanoma treated beyond progression: analysis of 2 phase 3 clinical trials. JAMA Oncol. 2017; 3: 1511 - 1519.
dc.identifier.citedreferenceSheskin DJ. Handbook of Parametric and Nonparametric Statistical Procedures. 5th ed. Boca Raton, FL: Chapman & Hall/CRC; 2011.
dc.identifier.citedreferenceAbdi H. The Bonferroni and Šidák corrections for multiple comparisons. In: Salkind NJ, ed. Encyclopedia of Measurement and Statistics. Thousand Oaks, CA: Sage; 2007: 103 - 107.
dc.identifier.citedreferenceClopper C, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika. 1934; 26: 404 - 413.
dc.identifier.citedreferenceBrookmeyer R, Crowley J. A confidence interval for the median survival time. Biometrics. 1982; 38: 29 - 41.
dc.identifier.citedreferenceKaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457 - 481.
dc.identifier.citedreferenceWolchok JD, Hoos A, O’Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009; 15: 7412 - 7420.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
cncr32190_am.pdf
Size:
527.3KB
Format:
PDF
View/Open
Name:
cncr32190.pdf
Size:
514.4KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.